文献速递肝病消化道肿瘤与早癌

FABP5阳性载脂巨噬细胞处理肿瘤来源不饱和脂肪酸信号抑制T细胞抗肿瘤免疫

FABP5+ lipid-loaded macrophages process tumour-derived unsaturated fatty acid signal to suppress T-cell antitumour immunity.
PubMed 文献 · J Hepatol · 2024-09-30

本研究通过单细胞RNA测序小鼠和人类肝细胞癌(HCC)样本,鉴定出一群FABP5阳性载脂肿瘤相关巨噬细胞(TAM),其表达增强的免疫检查点配体和免疫抑制分子。机制上,肿瘤细胞释放的长链不饱和脂肪酸(UFA)经FABP5激活PPARγ,赋予TAM免疫抑制特性;巨噬细胞FABP5缺失可降低免疫抑制分子表达、增强T细胞依赖性抗肿瘤免疫、减缓HCC生长并提高免疫治疗疗效。

要点

  • 单细胞RNA测序鉴定出FABP5阳性载脂TAM亚群,高表达免疫检查点配体和免疫抑制分子。
  • 肿瘤来源长链UFA经FABP5激活PPARγ,诱导TAM免疫抑制特性。
  • 巨噬细胞FABP5缺失增强T细胞抗肿瘤免疫、减缓HCC生长并改善免疫治疗疗效。

核心结论

  • 不饱和脂肪酸通过FABP5-PPARγ信号增强免疫抑制性肿瘤微环境促进肿瘤发生,靶向该通路改善肿瘤免疫治疗疗效具概念验证性。

研究设计与样本

  • 对小鼠和人类HCC肿瘤样本行单细胞RNA测序以阐明HCC TAM图谱。
  • 体外用多种长链不饱和脂肪酸刺激巨噬细胞评估免疫抑制分子表达。
  • 使用巨噬细胞特异性FABP5或PPARγ缺陷小鼠进行体内和体外研究。

主要发现

  • 在癌基因突变HCC小鼠模型和人类HCC肿瘤中鉴定出FABP5阳性载脂TAM亚群,其特征为免疫检查点阻断配体和免疫抑制分子增强。
  • 肿瘤细胞释放的长链UFA经FABP5激活PPARγ,导致TAM获得免疫抑制特性。
  • 巨噬细胞FABP5缺失降低免疫抑制分子表达,增强T细胞依赖性抗肿瘤免疫,减缓HCC生长,并改善免疫治疗疗效。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Tumour-associated macrophages (TAMs) contribute to hepatocellular carcinoma (HCC) progression. However, while the pro-tumour and immunosuppressive roles of lipid-loaded macrophages are well established, the mechanisms by which lipid metabolism enhances the tumour-promoting effects of TAMs remain unclear. METHODS: Single-cell RNA sequencing was performed on mouse and human HCC tumour samples to elucidate the landscape of HCC TAMs. Macrophages were stimulated with various long-chain unsaturated fatty acids (UFAs) to assess immunosuppressive molecule expression in vitro. Additionally, in vivo and in vitro studies were conducted using mice with macrophage-specific deficiencies in fatty acid-binding protein 5 (FABP5) or peroxisome proliferator-activated receptor γ (PPARγ). RESULTS: Single-cell RNA sequencing identified a subpopulation of FABP5+ lipid-loaded TAMs characterized by enhanced immune checkpoint blocker ligands and immunosuppressive molecules in an oncogene-mutant HCC mouse model and human HCC tumours. Mechanistically, long-chain UFAs released by tumour cells activate PPARγ via FABP5, resulting in immunosuppressive properties in TAMs. FABP5 deficiency in macrophages decreases immunosuppressive molecule expression, enhances T cell-dependent antitumour immunity, diminishes HCC growth, and improves immunotherapy efficacy. CONCLUSIONS: This study demonstrates that UFAs promote tumourigenesis by enhancing the immunosuppressive tumour microenvironment via FABP5-PPARγ signalling and provides a proof-of-concept for targeting this pathway to improve the efficacy of tumour immunotherapy. IMPACT AND IMPLICATIONS: Despite the role of tumour-associated macrophages (TAMs) in promoting tumour progression being well established, the mechanisms by which lipid metabolism enhances the tumour-promoting effects of TAMs remain unclear. Our study reveals that FABP5-mediated unsaturated fatty acid metabolism in TAMs is crucial for modulating antitumour T-cell immunity and influencing the efficacy of immunotherapy. This finding provides novel insights into the immunomodulatory roles of FABP5+ lipid-loaded TAMs in hepatocellular carcinoma and suggests that targeting FABP5 could offer a new approach to liver cancer treatment.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Yang X, Deng B, Zhao W, et al. FABP5+ lipid-loaded macrophages process tumour-derived unsaturated fatty acid signal to suppress T-cell antitumour immunity. J Hepatol. 2024. PMID: 39357545. doi:10.1016/j.jhep.2024.09.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。